Because the single-agent activities of these inhibitors have been modest in clinical trials, combination therapies with currently-used cancer drugs have demonstrated beneficial effects for the PI3K/AKT/mTOR inhibitors37,38; anti-HER2 therapies represent promising combination partners. This evidence concerns the gene ERBB2 and cancer.